Schou H S
Laegemiddelafdelingen, Sundhedsstyrelsen, København.
Ugeskr Laeger. 1993 Jun 28;155(26):2024-8.
Price developments for the first parallel imported preparations and the corresponding original preparations have been followed over the period 1st January 1992 to 1st June 1992 with the aim of registering any possible effects of the parallel import on price levels. Altogether 174 parallel imported preparations--including different strengths and administration forms--received marketing permission in the period, and by 1st June 1992 74 parallel imported preparations had come on the market. The main part of the parallel imported preparations are marketed at a lower price than the original preparations. At the end of the investigation period, 56% of the marketed parallel imported preparations were being sold at a price that was on average 5-10% below that of the corresponding original preparation; 24% were being sold at a price 0-4% below the original and 20% were being sold at more than 10% below the original preparations. The effect on the prices of the original preparations has been variable. In the beginning of the study period we saw four examples of large reductions in the price of original preparations (up to 45%) after the parallel imports began to be marketed, but at the end of the study period the marketing of the cheaper preparations seemed to have no effect on the prices of the original preparations, which remained unchanged.
1992年1月1日至1992年6月1日期间，对首批平行进口制剂及其相应原研制剂的价格变化进行了跟踪，目的是记录平行进口对价格水平可能产生的任何影响。在此期间，共有174种平行进口制剂（包括不同规格和剂型）获得了上市许可，截至1992年6月1日，已有74种平行进口制剂上市。平行进口制剂的主要部分以低于原研制剂的价格销售。在调查期结束时，56%的已上市平行进口制剂的售价平均比相应原研制剂低5%至10%；24%的售价低于原研制剂0%至4%；20%的售价低于原研制剂超过10%。对原研制剂价格的影响各不相同。在研究期开始时，我们看到有四个例子，平行进口制剂开始上市后，原研制剂价格大幅下降（高达45%），但在研究期结束时，较便宜制剂的上市似乎对原研制剂价格没有影响，价格保持不变。
